CLPT vs. INMD, CDRE, MDXG, RXST, BLFS, AORT, EMBC, PLSE, LQDA, and ESTA
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include InMode (INMD), Cadre (CDRE), MiMedx Group (MDXG), RxSight (RXST), BioLife Solutions (BLFS), Artivion (AORT), Embecta (EMBC), Pulse Biosciences (PLSE), Liquidia (LQDA), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.
ClearPoint Neuro vs.
InMode (NASDAQ:INMD) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking.
InMode has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
InMode received 139 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 88.00% of users gave ClearPoint Neuro an outperform vote while only 73.85% of users gave InMode an outperform vote.
In the previous week, InMode had 3 more articles in the media than ClearPoint Neuro. MarketBeat recorded 3 mentions for InMode and 0 mentions for ClearPoint Neuro. InMode's average media sentiment score of 0.21 beat ClearPoint Neuro's score of 0.00 indicating that InMode is being referred to more favorably in the media.
InMode has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
68.0% of InMode shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
InMode has a net margin of 36.26% compared to ClearPoint Neuro's net margin of -59.64%. InMode's return on equity of 21.46% beat ClearPoint Neuro's return on equity.
InMode currently has a consensus price target of $22.40, indicating a potential upside of 33.41%. ClearPoint Neuro has a consensus price target of $11.33, indicating a potential downside of 24.65%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than ClearPoint Neuro.
Summary
InMode beats ClearPoint Neuro on 14 of the 18 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
This page (NASDAQ:CLPT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CLPT Stock Alerts